CRISPR Therapeutics AG (CRSP) Equity Income (2018 - 2019)
CRISPR Therapeutics AG (CRSP) posted Equity Income of $22.6 million for Q3 2019, up 24.86% sequentially from $18.1 million in Q2 2019, and up 67.41% YoY from $13.5 million in Q3 2018.
CRISPR Therapeutics AG (CRSP) Equity Income (2018 - 2019) Analysis & Trends
CRISPR Therapeutics AG has reported Equity Income for 2 years, with the latest figure at $22.6 million in Q3 2019.
- Quarterly Equity Income rose 67.41% year-over-year to $22.6 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $81.6 million (changed N/A YoY) and the FY2018 annual result came in at $52.5 million, up 45.03% from the prior year.
- Equity Income advanced to $22.6 million in Q3 2019 per CRSP's latest filing, from $18.1 million in the prior quarter.
- Over five years, Equity Income peaked at $26.7 million in Q4 2018 and troughed at $13.5 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 22.60 Mn |
| Jun 30, 2019 | 18.10 Mn |
| Mar 31, 2019 | 14.20 Mn |
| Dec 31, 2018 | 26.70 Mn |
| Sep 30, 2018 | 13.50 Mn |
| Jun 30, 2018 | 13.50 Mn |